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We  compared  the  effects  of bone  marrow-derived  mononuclear  cells  (BMMCs)  and mesenchymal  stro-
mal cells  (MSCs)  on airway  inﬂammation  and  remodeling  and  lung  mechanics  in experimental  allergic
asthma.  C57BL/6  mice  were  sensitized  and  challenged  with  ovalbumin  (OVA  group).  A control  group
received  saline  using  the  same  protocol.  Twenty-four  hours  after  the  last  challenge,  groups  were  further
randomized  into  subgroups  to receive  saline,  BMMCs  (2 ×  106)  or MSCs  (1  × 105) intratracheally.  BMMC
and MSC  administration  decreased  cell  inﬁltration,  bronchoconstriction  index,  alveolar  collapse,  collagenulmonary eosinophilia
ﬁber  content  in  the  alveolar  septa,  and  interleukin  (IL)-4,  IL-13,  transforming  growth  factor  (TGF)-  and
vascular  endothelial  growth  factor  (VEGF)  levels  compared  to OVA-SAL.  Lung  function,  alveolar  collapse,
collagen ﬁber  deposition  in  alveolar  septa,  and  levels  of  TGF-  and  VEGF  improved  more  after  BMMC
than  MSC  therapy.  In conclusion,  intratracheal  BMMC  and  MSC  administration  effectively  modulated
inﬂammation  and  ﬁbrogenesis  in  an  experimental  model  of  asthma,  but  BMMCs  was  associated  with
greater beneﬁt  in terms  of  reducing  levels  of  ﬁbrogenesis-related  growth  factors.. Introduction
Asthma is a chronic inﬂammatory disease of the airways
Murphy and O’Byrne, 2010) associated with structural changes
uch as subepithelial ﬁbrosis, mucous metaplasia, wall thickening,
mooth muscle cell hypertrophy and hyperplasia, myoﬁbroblast
yperplasia, vascular proliferation, and extracellular matrix abnor-
alities (Al-Muhsen et al., 2011). These changes accelerate decline
n lung function despite treatment with inhaled corticosteroids.
herefore, new strategies that can hasten the repair process and
ttenuate airway inﬂammation and remodeling are warranted.
Several recent studies have investigated the impact of bone
arrow-derived mononuclear cells (BMMCs) (Abreu et al.,
011) or mesenchymal stromal cells (MSCs) (Firinci et al., 2011;
oodwin et al., 2011; Ou-Yang et al., 2011; Kapoor et al., 2012)n experimental allergic asthma. Each has speciﬁc advantages.
MMCs  can be used in autologous transplantation, on the same
ay of harvesting, and avoid common complications such as
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Open access under the Elsevier OA license. © 2013 Elsevier B.V. 
graft-versus-host disease, whereas MSCs exhibit multilineage
differentiation potential and immune-privileged features and
enable allogenic use (Mathieu et al., 2009; Lu et al., 2011). So far,
however, no study has evaluated the effects of cell type in cell
therapy of experimental asthma. Furthermore, most cell therapies
have been studied at the onset of the remodeling process; there
are no data on the effects of cell therapy once the remodeling
process of asthma is already established. Within this context, the
present study sought to investigate and compare the therapeutic
effects of BMMCs  or MSCs on lung mechanics and histology,
collagen ﬁber content in the airway and alveolar septa, and levels
of cytokines and growth factors in lung tissue in a murine model
of experimental allergic asthma.
2. Materials and methods
This study was approved by the Ethics Committee of the Health
Sciences Center, Federal University of Rio de Janeiro.
2.1. Extraction and characterization of BMMCs and MSCs
Open access under the Elsevier OA license. BMMCs  and MSCs were obtained from male C57BL/6 mice
(weight 20–25 g, n = 5 per group) and administered on the day
of collection or after 3 passages, respectively. Bone marrow cells
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uig. 1. Study design. (A) Schematic ﬂow chart and (B) timeline of the study. Experi
hallenged with ovalbumin; SAL, mice treated with saline; BMMC, mice treated wi
he  last challenge (1 × 105). All data were analyzed on day 54.
ere aspirated from the femur and tibia by ﬂushing the bone
arrow cavity with Dulbecco’s modiﬁed Eagle’s medium (DMEM)
Life Technologies, Grand Island, NY, USA). After a homogeneous
ell suspension was achieved, cells were centrifuged (400 × g
or 10 min), plated in DMEM containing 20% fetal bovine serum
MSCs) or re-suspended in DMEM (BMMCs) and added to Ficoll-
ypaque (Histopaque 1083, Sigma Chemical Co., St. Louis, MO,
SA), and again centrifuged and supplemented with phosphate-
uffered saline (PBS). Cell characterization was  performed by
ow cytometry using antibodies against CD45 (leukocytes), CD34
hematopoietic precursors), CD3, CD8, and CD4 (T lymphocytes),
D19 (B lymphocytes), CD14 (monocytes), and CD11b, CD29 and
D45 (non-hematopoietic precursors) (BD Biosciences, USA). The
bsence of CD34 and CD45 and the presence of CD14, CD29,
nd Sca-1 were used to identify MSCs. Furthermore, MSCs were
dentiﬁed by the capacity to differentiate into osteoblasts and
hondroblasts.
.2. Animal preparation and experimental protocol
Thirty-six female C57BL/6 mice (weight, 20–25 g) were ran-
omly assigned to two groups. In the OVA group, mice were
mmunized using an adjuvant-free protocol by intraperitoneal
njection of sterile ovalbumin (OVA, 10 g OVA in 100 l saline)
n 7 alternate days. Forty days after the start of sensitization, 20 g
f OVA in 20 l of saline were instilled intratracheally. This proce-
ure was performed 3 times at 3-day intervals (Xisto et al., 2005).
he control group (C) received saline using the same protocol. The C
nd OVA groups were further randomized to receive saline solution
0.9% NaCl, 50 l, SAL), BMMCs  (2 × 106 in 50 l) or MSCs (1 × 105
n 50 l) intratracheally, 24 h after the last challenge (Fig. 1). For
he administration of saline, BMMCs  or MSCs, mice were anes-
hetized with sevoﬂurane, the trachea of each mouse was  dissected,
nd cells were slowly injected. Furthermore, small aliquots were
sed for immunophenotypic ﬂow cytometry characterization ofl groups: C, mice sensitized and challenged with saline; OVA, mice sensitized and
MC 24 h after the last challenge (2 × 106); MSC, mice treated with MSCs 24 h after
the injected cell populations and to evaluate the ability of MSCs
to differentiate into osteoblasts and chondroblasts (Fig. 2).
2.3. Mechanical parameters
One week after cell therapy, the animals were sedated
(diazepam 1 mg i.p.), anesthetized (thiopental sodium 20 mg/kg
i.p.), tracheotomized, paralyzed (vecuronium bromide,
0.005 mg/kg i.v.), and ventilated with a constant ﬂow ventilator
(Samay VR15; Universidad de la Republica, Montevideo, Uruguay)
set to the following parameters: frequency 100 breaths/min, tidal
volume (VT) 0.2 mL,  and fraction of inspired oxygen (FiO2) 0.21.
The anterior chest wall was  surgically removed and a positive
end-expiratory pressure of 2 cm H2O applied. Airﬂow and tracheal
pressure (Ptr) were measured. Lung mechanics were analyzed
by the end-inﬂation occlusion method. In an open chest prepa-
ration, Ptr reﬂects transpulmonary pressure (PL). Brieﬂy, after
end-inspiratory occlusion, there is a rapid initial decline in PL
(P1,L) from the preocclusion value down to an inﬂection point
(Pi), followed by a slow pressure decay (P2,L), until a plateau is
reached. This plateau corresponds to the elastic recoil pressure
of the lung (Pel). P1,L selectively reﬂects the pressure used to
overcome airway resistance. P2,L reproduces the pressure spent
by stress relaxation, or the viscoelastic properties of the lung, as
well as a small contribution of pendelluft. Static lung elastance
(Est,L) was  determined by dividing Pel by VT. Lung mechanics mea-
surements were obtained 10 times in each animal. All data were
analyzed using ANADAT software (RHT-InfoData, Inc., Montreal,
Quebec, Canada). All experiments lasted less than 15 min.
2.4. Lung histologyLaparotomy was  performed immediately after determination
of lung mechanics. Heparin (1000 IU) was injected into the vena
cava. The trachea was clamped at end-expiration, and the abdom-
inal aorta and vena cava were sectioned, producing massive
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Cig. 2. Flow cytometry analysis and potential of differentiation of the injected MS
D14−/CD34−.  (D) Cells CD29+ and Sca1+. (E) Osteoblasts and (F) chondroblasts di
emorrhage and terminal bleeding for euthanasia. The right lung
as then removed, ﬁxed in 3% buffered formalin and embed-
ed in parafﬁn; 4-m-thick slices were cut and stained with
ematoxylin–eosin.
ig. 3. Lung mechanics. (A) Lung static elastance (Est,L); (B) resistive pressure (P1,L)
hallenged with saline; OVA, mice sensitized and challenged with ovalbumin; SAL, mice g
SC,  mice treated with MSC  24 h after the last challenge (1 × 105). Box plots show media
-SAL  (p < 0.05). **Signiﬁcantly different from OVA-SAL (p < 0.05). #Signiﬁcantly different Cells CD45+ and CD45−. (B) Cells CD45+ and CD14+/CD34+. (C) Cells CD45− and
tiation.
Lung histology analysis was  performed with an integrating
eyepiece with a coherent system consisting of a grid with 100
points and 50 lines (known length) coupled to a conventional
light microscope (Olympus BX51, Olympus Latin America-Inc.,
; (C) viscoelastic (P2,L) pressures. Experimental groups: C, mice sensitized and
iven saline; BMMC,  mice treated with BMMC  24 h after the last challenge (2 × 106);
ns and interquartile ranges for 6 mice in each group. *Signiﬁcantly different from
 from OVA-BMMC (p < 0.05).
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Table 1
Morphometric parameters.
Groups Normal area (%) Alveolar collapse (%) MN (%) PMN  (%) Contraction index
C
SAL 99 (91–100) 1 (0–1) 32.3 (29.8–37.9) 0.20 (0–0.99) 2.15 (1.9–2.8)
BMMC  99 (91–100) 1 (0–1) 28 (24.3–36) 3.48 (2.04–4.01)* 2.44 (1.5–2.5)
MSC  99 (91–100) 1 (0–1) 27.7 (23.6–32) 1.03(0.84–2.5)* 2.26 (1.2–2.4)
OVA
SAL  47 (37–58)* 53 (42–63)* 52.5 (47.3–56.1)* 6.94 (6.15–8.89)* 3.06 (2.8–3.9)*
BMMC 91 (74–95)*,** 9 (8–26)*,** 29.4 (26.4–31) 3.26 (3.03–6.07)*,** 2.08 (1.4–2.9)**
MSC  75 (72–75)*,** ,# 25 (5–27)*,** ,# 29.4 (26.4–32) 3.93 (2.85–4.42)*,** 2.13 (1.8–2.5)**
Values expressed as median (interquartile range) of 6 animals per group. All values were computed in 10 random, non-coincident ﬁelds per mouse. Fractional area of normal
and  collapsed alveoli, mononuclear (MN) and polymorphonuclear (PMN) cells, and contraction index. Experimental groups: C, mice sensitized and challenged with saline;
OVA,  mice sensitized and challenged with ovalbumin; SAL, mice given saline; BMMC,  mice treated with BMMC  24 h after the last challenge (2 × 106); MSC, mice treated with
MSC  24 h after the last challenge (1 × 105).
* Signiﬁcantly different from C-SAL (p < 0.05).
** Signiﬁcantly different from OVA-SAL (p < 0.05).
# Signiﬁcantly different from OVA-BMMC (p < 0.05).
Fig. 4. Representative photomicrographs of lung parenchyma (upper panels) and airways (lower panels), hematoxylin–eosin stain. Collapsed areas in the lung parenchyma
and  a reduction in central airway diameter, as well as increased cell inﬁltration, are visible in the OVA-SAL animals. Experimental groups: C, mice sensitized and challenged
with saline; OVA, mice sensitized and challenged with ovalbumin; SAL, mice given saline; BMMC, mice treated with BMMC  24 h after the last challenge (2 × 106); MSC, mice
treated  with MSC 24 h after the last challenge (1 × 105). Original magniﬁcation: 200× and 400× (upper and lower panels, respectively). Bars = 100 m.
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Fig. 5. Collagen ﬁber content in the lung parenchyma and airways. Experimental groups: C, mice sensitized and challenged with saline; OVA, mice sensitized and challenged
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p  < 0.05). #Signiﬁcantly different from OVA-BMMC (p < 0.05).
razil). The volume fraction of collapsed and normal pulmonary
reas, the magnitude of bronchoconstriction (contraction index),
nd the number of mononuclear and polymorphonuclear cells
n pulmonary tissue were determined by the point-counting
echnique across 10 random, non-coincident microscopic ﬁelds
Weibel, 1990; Hsia et al., 2010).
Collagen was quantiﬁed in the airways and alveolar septa by the
icrosirius polarization method, using Image-Pro Plus 6.0 software
Xisto et al., 2005; Antunes et al., 2009, 2010).
.5. Enzyme-linked immunosorbent assay (ELISA)
Levels of interleukin (IL)-4, IL-13, transforming growth factor
TGF)- and vascular endothelial growth factor (VEGF) in lung tis-
ue were evaluated by ELISA using matched antibody pairs from
repoTech and R&D Systems (Minneapolis, MN,  USA), according to
anufacturer instructions. Results are expressed as pg/mL.
.6. Statistical analysis
One-way ANOVA on ranks followed by Dunn’s test was used for
omparison of between-group differences. Data were expressed as
edians and interquartile ranges. All tests were performed using
he SigmaStat 3.1 software package (Jandel Corporation, San Rafael,
A, USA), and statistical signiﬁcance was established as p < 0.05.
. Results
The following subpopulations were identiﬁed in the
ool of injected BMMCs: total lymphocytes (lower SSC,
D45+/CD11+/CD29−/CD34− = 19.6%), T lymphocytes (lower SSC/
D45+/CD3+/CD34− = 5.4%), T helper lymphocytes (CD3+/CD4+/
D8− = 1.98%), cytotoxic T lymphocytes (CD3+/CD4−/CD8+
 5.06%), monocytes (CD45+/CD29+/CD11b+ low/CD34−/CD3−
 7.24%), hematopoietic progenitors (CD34+/CD45+ = 2.65%), and
ossible MSCs (CD45−/CD34−/CD11b−  = 3.8%). Similarly, MSCs
ere characterized as CD45−/CD14−/CD34−/CD29+/Sca1+ and
ere capable of differentiation into osteoblasts and chondroblasts
Fig. 2). The number of MSCs administered was similar to that
resent in the pool of BMMCs.
According to lung function analysis, the OVA-SAL groups exhib-
ted higher Est,L (57%), P1,L (76%), and P2,L (53%) as compared
ith the C-SAL group. Both cell therapies were effective for reduc-
ion of P1,L and P2,L. However, these decrements were more
ronounced after BMMC  therapy than MSC  therapy. Furthermore, last challenge (2 × 106); MSC, mice treated with MSC  24 h after the last challenge
igniﬁcantly different from C-SAL (p < 0.05). **Signiﬁcantly different from OVA-SAL
only BMMC  therapy was  associated with a signiﬁcant decrease in
Est,L (Fig. 3).
Lung morphometric examination demonstrated a signiﬁcant
increase in fractional area of alveolar collapse, contraction index,
number of mononuclear and polymorphonuclear cells, and colla-
gen ﬁber content in the airways and alveolar septa in the OVA-SAL
group compared to the C-SAL group (Table 1 and Figs. 4 and 5). Both
cell therapies minimized the fractional area of alveolar collapse
and polymorphonuclear cell inﬁltration in lung tissue (Table 1 and
Fig. 4), and completely reversed changes in the contraction index
(Table 1) and airway wall thickness (Fig. 4). Furthermore, both ther-
apies decreased the amount of collagen ﬁber, speciﬁcally in the
alveolar septa. BMMC  therapy led to a more signiﬁcant reduction
in alveolar collapse and collagen ﬁber deposition in alveolar septa
as compared with MSC  therapy (Table 1 and Figs. 5 and 6). No sig-
niﬁcant difference was observed in the amount of collagen ﬁber in
the airways after both therapies (Figs. 5 and 6).
Levels of IL-4, IL-13, TGF- and VEGF in lung tissue were
higher in the OVA-SAL group than in the C-SAL group. BMMC and
MSC  administration yielded similar reductions in IL-4 and IL-13,
whereas TGF- and VEGF levels presented a greater reduction after
BMMC  therapy than after MSC  therapy (Fig. 7).
4. Discussion
In the murine model of allergic asthma used herein, BMMC  and
MSC  administration yielded similar beneﬁcial effects on airway
inﬂammation, as shown by signiﬁcant reductions in the number
of mononuclear and polymorphonuclear cells and in the levels of
pro-inﬂammatory cytokines (IL-4 and IL-13) in lung tissue. How-
ever, BMMC  administration led to greater improvement in lung
mechanics and a greater reduction in fractional area of alveolar col-
lapse, collagen ﬁber content in the alveolar septa, and growth factor
levels (TGF- and VEGF) as compared with MSCs. Our ﬁndings sug-
gest that both cell types play an important role in the inﬂammatory
process in experimental allergic asthma, but suggest that BMMCs
are more effective than MSCs at reducing the remodeling process.
Several studies have investigated the effects of BMMC (Abreu
et al., 2011) and MSC  (Goodwin et al., 2011; Ou-Yang et al., 2011;
Kapoor et al., 2012) administration in experimental asthma. We
have previously demonstrated that pre-treatment with BMMCs
curtails airway inﬂammation and remodeling and induces lung
repair, thus improving lung mechanics (Abreu et al., 2011). The
rationale supporting BMMC  therapy relies on the knowledge that
the functional effects of these cells result from a balance between
different cell types, with involvement of all cells with the potential
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Fig. 6. Representative photomicrographs of lung parenchyma (upper panels) and airways (lower panels), Picrosirius stain. Marked deposition of collagen ﬁbers is visible
in  the OVA-SAL groups. Experimental groups: C, mice sensitized and challenged with saline; OVA, mice sensitized and challenged with ovalbumin; SAL, mice given saline;
BMMC,  mice treated with BMMC  24 h after the last challenge (2 × 106); MSC, mice treated with MSC  24 h after the last challenge (1 × 105). Original magniﬁcation: 200× and
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o yield beneﬁcial effects (Mathieu et al., 2009; Araujo et al., 2010;
u et al., 2011; Cruz et al., 2012). This hypothesis is supported by the
rosstalk between multiple cell types that occurs during embryonic
evelopment (Raﬁi and Lyden, 2003). Additionally, BMMCs  can be
dministered easily and safely, on the day of harvesting, at lower
osts, and without risk of cell rejection (graft-versus-host disease).
SCs also lead to beneﬁcial effects in experimental asthma when
dministered during sensitization or before challenge (Firinci et al.,
011; Goodwin et al., 2011; Lee et al., 2011). MSCs exhibit multilin-
age differentiation potential (Jiang et al., 2002), support adequate
issue repair, have immune-privileged features and can be used in
llogeneic therapy.
No previous study has compared the effects of BMMCs  and
SCs in experimental asthma, particularly once the remodeling
rocess is already established. For this purpose, we  employed
 C57BL/6 mouse model of allergic asthma (Abreu et al., 2011),
hich features eosinophilia and Th2 pro-inﬂammatory cytokines
Yu et al., 2006; Allen et al., 2012). Even though early therapy with
MMCs  modulates lung inﬂammation and remodeling regardless
f the route of administration (Abreu et al., 2012), in the present
tudy, both cell types were instilled intratracheally, since a more
irect administration route will ensure delivery of a higher numberof cells to the airway and alveoli (Bonios et al., 2011). To ascertain
whether the effects of BMMC  therapy resulted from the balance
between cell types rather than strictly from the presence of MSCs
in the bone marrow pool, approximately the same number of MSCs
found in the bone marrow mononuclear fraction according to ﬂow
cytometry was administered to the OVA-MSC group (4% MSCs in
2 × 106 BMMCs, approximately 1 × 105 MSCs).
Asthma is an inﬂammatory disease classically associated with
increased expression of T helper 2 (Th2) cytokines, mainly IL-
4 and IL-13. Among other functions, these cytokines induce Th2
differentiation bias, ﬁbroblast proliferation, extracellular matrix
deposition, airway hyperresponsiveness, epithelial cell apopto-
sis, mucus production, and eosinophil recruitment (Hamid and
Tulic, 2009). Therefore, they play important roles not only in the
inﬂammatory process, but also in airway remodeling, and are thus
considered important therapeutic targets (Borowski et al., 2008;
Bellini et al., 2011). In this context, both BMMC  and MSC  cell thera-
pies were found to reduce IL-4 and IL-13 levels, possibly as a result
of the decrease in eosinophil inﬁltration and collagen ﬁber content
in alveolar septa. Interestingly, these cells were unable to reduce
airway ﬁbrosis, which may  be explained by the onset of the col-
lagen deposition process before initiation of cell therapy, unlike
196 S.C. Abreu et al. / Respiratory Physiology & Neurobiology 187 (2013) 190– 198
Fig. 7. Levels of IL-4, IL-13, TGF-, and VEGF in lung tissue. Experimental groups: C, mice sensitized and challenged with saline; OVA, mice sensitized and challenged with
ovalbumin; SAL, mice given saline; BMMC,  mice treated with BMMC  24 h after the last challenge (2 × 106); MSC, mice treated with MSC  24 h after the last challenge (1 × 105).
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Signiﬁcantly different from OVA-BMMC (p < 0.05).
revious studies in which cells were administrated as pretreatment
nd, therefore, before the ultrastructural changes characteristic of
he remodeling process had occurred (Abreu et al., 2011; Goodwin
t al., 2011). Further studies are recommended to assess whether
ong-term treatment and the administration of repeated doses of
ither cell type could further reduce collagen ﬁber content in the
irways.
Both BMMC  and MSC  administration were effective in mini-
izing lung remodeling in the present model of allergic asthma.
owever, BMMCs  promoted a more marked reduction of TGF-
nd VEGF levels than MSCs. TGF- is a proﬁbrotic agent, pro-
uced by epithelium, ﬁbroblasts and inﬂammatory cells (mainly
osinophils) (Minshall et al., 1997; Lee et al., 2001). It is capable
f inducing epithelial detachment, epithelial–mesenchymal transi-
ion, subepithelial ﬁbrosis, and airway smooth muscle hyperplasia
nd migration, and plays an important role in airway remodel-
ng (Halwani et al., 2011). The reduction in TGF- observed in the
resent study was consistent with a previous report (Abreu et al.,
011), while another study associated the beneﬁcial effects of MSC
herapy with stimulation of TGF- expression (Nemeth et al., 2010).
GF- also contributes to the increased vascularity of asthmatic
irways through induction of VEGF, a key angiogenic molecule
Willems-Widyastuti et al., 2011) that plays a prominent role in
he remodeling process in experimental asthma (Lee et al., 2006).
EGF levels also declined after BMMC  and MSC  therapy, in close
orrelation with the changes observed in TGF- levels. Therefore,
t seems that BMMC  and, less efﬁciently, MSC  administration mod-
late steps in the airway remodeling pathway involving IL-4, IL-13,
osinophils, TGF-, and VEGF.Although the pathologic characteristics of asthma are well
nown, the association between these features and physiological
mpairment is less clear. Furthermore, it is noteworthy that not only
entral airways, but also distal airways and lung parenchyma, arey different from C-SAL (p < 0.05). **Signiﬁcantly different from OVA-SAL (p < 0.05).
involved in the functional changes of asthma (Xisto et al., 2005).
In the experimental model of allergic asthma used herein, we
observed histological changes such as increased alveolar collapse
and contraction index, which were due to alterations in airway
wall thickness and collagen ﬁber deposition. These morphological
changes led to increased lung static elastance and viscoelastic and
resistive pressures respectively. Both cell therapies decreased resis-
tive pressure, probably due to an increase in the internal diameter of
the central airways and a reduction in collagen ﬁber content in the
distal airways. BMMC  therapy led to a more pronounced reduction
in viscoelastic pressure and static elastance than MSC  administra-
tion, a ﬁnding that may  be associated with explain less alveolar
collapse and reduction in collagen deposition in the alveolar septa
in the OVA-BMMC group. These results corroborate the ﬁndings of
a previous study that evaluated the role of BMMC  therapy using
the same experimental protocol (Abreu et al., 2011). Therefore,
the fact that the reduction in these histological changes was more
pronounced with BMMC  therapy may  be associated with greater
improvement in lung mechanics.
The clinical implication of these ﬁndings is associated with
the advantages of using BMMCs  over MSCs, namely the fact that
BMMCs  may  be used in autologous transplantation (thus avoiding
potential cell rejection) and on the same day of harvesting.
This study has some limitations. First, saline was administrated
rather than ﬁbroblasts, since ﬁbroblasts have been shown to yield
no beneﬁcial effects (Xu et al., 2007). Furthermore, it is speculated
that MSCs constitute a unique cell type, distinct from ﬁbroblasts
(Martinez et al., 2007). Second, other cytokines and growth fac-
tors in addition to those analyzed in this study may be involved
in the airway remodeling process. Third, even though the num-
ber of animals in each group was relatively small (n = 6), three
sets of experiments were conducted to assess reproducibility and
reliability. Finally, BMMCs  are a heterogeneous mix that includes
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ematopoietic cells, a variety of inﬂammatory cell types, and a
mall number of cells with phenotypic characteristics of MSCs. Pre-
linical models have demonstrated that the hematopoietic fraction
ould differentiate into lineages that could regenerate damaged
issue (Lakshmipathy and Verfaillie, 2005), whereas MSCs have
mmunomodulatory properties and release trophic factors, accel-
rating the repair process and regenerating viable tissue, thereby
mproving lung function (Ou-Yang et al., 2011). The present study
as unable to evaluate which combination of cells observed in the
MMC  pool yielded better effects. Further studies are warranted to
valuate additional mechanisms of action of BMMCs  and MSCs, as
ell as the potential role of the combination of different cell types
ound in BMMCs.
In conclusion, in the murine model of allergic asthma used
erein, both BMMC  and MSC  administration were effective in
educing airway inﬂammation and remodeling and improving lung
unction. However, the improvement in lung mechanics and his-
ology was more evident after BMMC  administration, suggesting
hat the interaction between the multiple cell types present in
he bone marrow mononuclear fraction plays an important role in
hese processes. These observations have several implications for
he framework of future clinical studies, due to the aforementioned
dvantages of BMMCs  over MSCs.
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